Suchergebnisse - "Hormonal/therapeutic use"

Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy

Autoren: Howell, Sacha J Howell, Anthony

Quelle: Advances in Experimental Medicine and Biology ISBN: 9783031708749
Howell, S J & Howell, A 2025, Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy. in A Guide to Breast Cancer Research : From Cellular Heterogeneity and Molecular Mechanisms to Therapy. Advances in Experimental Medicine and Biology, vol. 1464, Springer Nature, pp. 449-474. https://doi.org/10.1007/978-3-031-70875-6_22

Schlagwörter: Selective Estrogen Receptor Modulators, Antineoplastic Agents, Hormonal/therapeutic use, Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Antineoplastic Agents, Breast Neoplasms, Breast Neoplasms/drug therapy, Estrogen Receptor Antagonists/therapeutic use, Receptors, Estrogen, Signal Transduction/drug effects, Selective Estrogen Receptor Modulators/therapeutic use, Receptors, Humans, Animals, Female, Estrogen/metabolism, Receptors, Estrogen/metabolism, Hormonal/therapeutic use, Molecular Targeted Therapy/methods, Aromatase Inhibitors/therapeutic use, Signal Transduction

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39821038
https://research.manchester.ac.uk/en/publications/79ac5dd8-2fdd-4734-bc60-6c0a12c34d02
https://doi.org/10.1007/978-3-031-70875-6_22

The Population-level Effect of Adjuvant Therapies on Breast Cancer Recurrence: Application of the Trend-in-Trend Design

Autoren: Lindsay J. Collin Lance A. Waller Deirdre P. Cronin-Fenton et al.

Quelle: Collin, L J, Waller, L A, Cronin-Fenton, D P, Ahern, T P, Goodman, M, McCullough, L E, Kjærsgaard, A, Woolpert, K M, Silliman, R A, Christiansen, P M, Ejlertsen, B, Toft Sørensen, H & Lash, T L 2024, 'The Population-level Effect of Adjuvant Therapies on Breast Cancer Recurrence : Application of the Trend-in-Trend Design', Epidemiology, vol. 35, no. 5, pp. 660-666. https://doi.org/10.1097/EDE.0000000000001753

Schlagwörter: Adult, Antineoplastic Agents, Hormonal/therapeutic use, Antineoplastic Agents, Hormonal, Receptor, ErbB-2, Denmark, Breast Neoplasms, population-level effect, Breast Neoplasms/drug therapy, Humans, Aged, Neoplasm Recurrence, Local/epidemiology, Trastuzumab/therapeutic use, Breast cancer recurrence, Pharmacoepidemiology, Middle Aged, Trastuzumab, Denmark/epidemiology, 3. Good health, Postmenopause, Tamoxifen, Tamoxifen/therapeutic use, Receptors, Estrogen, Premenopause, Chemotherapy, Adjuvant, pharmacoepidemiology study design, Female, adjuvant therapies, Neoplasm Recurrence, Local

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39109817

An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)

Autoren: Trozzi, Rita Tuyaerts, Sandra Annibali, Daniela et al.

Weitere Verfasser: Trozzi, Rita Tuyaerts, Sandra Annibali, Daniela et al.

Quelle: International journal of gynecological cancer
International Journal Of Gynecological Cancer

Schlagwörter: Ovarian Neoplasms, Adult, Fulvestrant/administration & dosage, Antineoplastic Agents, Hormonal/therapeutic use, Sex Cord-Gonadal Stromal Tumors/drug therapy, Antineoplastic Agents, Hormonal, Genital Neoplasms, Female, Genital Neoplasms, Female/drug therapy, Ovarian Neoplasms/drug therapy, Middle Aged, 3. Good health, 03 medical and health sciences, Neoplasm Recurrence, Local/drug therapy, 0302 clinical medicine, Receptors, Estrogen, Sex Cord-Gonadal Stromal Tumors, Humans, Female, Human medicine, Prospective Studies, Receptors, Estrogen/metabolism, Neoplasm Recurrence, Local, Fulvestrant, Aged

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40228941
https://pubmed.ncbi.nlm.nih.gov/38724237
https://hdl.handle.net/10067/2060640151162165141
https://biblio.vub.ac.be/vubir/an-openlabel-singlearm-prospective-multicenter-tandem-twostage-designed-phase-ii-study-to-evaluate-the-efficacy-of-fulvestrant-in-women-with-recurrentmetastatic-estrogen-receptorpositive-gynecological-malignancies-fuchsia-study(82bb6b14-67c9-43b4-a6dd-d8e53225ce35).html

The gut microbiota during tamoxifen therapy in patients with breast cancer

Autoren: Lars E. Hillege David J. M. Barnett Janine Ziemons et al.

Quelle: Sci Rep
Scientific Reports, Vol 15, Iss 1, Pp 1-12 (2025)

Schlagwörter: Feces/microbiology, Tamoxifen/therapeutic use pharmacology analogs & derivatives, Antineoplastic Agents, Hormonal, Science, Antineoplastic Agents, Breast Neoplasms, Article, Feces, RNA, Ribosomal, 16S, Antineoplastic agents, Humans, Gastrointestinal Microbiome/drug effects, Prospective Studies, Hormonal/therapeutic use, Aged, Ribosomal, Middle Aged, Gastrointestinal Microbiome, Postmenopause, Tamoxifen, Breast Neoplasms/drug therapy microbiology metabolism, RNA, Medicine, Postmenopausal, Female, Breast neoplasms, 16S/genetics

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40050324
https://doaj.org/article/d0c979e93b0a4833a1a5df373006e020
https://cris.maastrichtuniversity.nl/en/publications/3dfb9994-4daf-4d55-9363-a86ddd3f0395
https://doi.org/10.1038/s41598-025-91734-1

Geographic Variations and the Associated Factors in Adherence to and Persistence with Adjuvant Hormonal Therapy for the Privately Insured women Aged 18–64 with Breast Cancer in Texas

Autoren: Junghyun Kim Man S. Kim Suja S. Rajan et al.

Weitere Verfasser: Junghyun Kim Man S. Kim Suja S. Rajan et al.

Quelle: Curr Oncol
Current Oncology, Vol 30, Iss 4, Pp 3800-3816 (2023)
Current Oncology; Volume 30; Issue 4; Pages: 3800-3816

Schlagwörter: Antineoplastic Agents, Hormonal, Antineoplastic Agents, Breast Neoplasms* / epidemiology, Breast Neoplasms, geographic variation, Article, Medication Adherence, Insurance, adjuvant hormonal therapy, breast cancer, adherence, persistence, Medical Specialties, Medicine and Health Sciences, Chemotherapy, Humans, Adjuvant, RC254-282, Retrospective Studies, Insurance, Health, Hormonal, Hormonal / therapeutic use, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Texas, 3. Good health, Oncology, Health, Chemotherapy, Adjuvant, Female, Public Health, Breast Neoplasms* / drug therapy

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37185401
https://doaj.org/article/73022fb7981d4d3dbb8fc6963d386ff9

Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2− Tumors Treated with Adjuvant Hormonal Therapy: A Real‐World Study in Croatia

Autoren: Dora Čerina Pavlinović Natalija Dedić Plavetić Ingrid Belac Lovasić et al.

Quelle: Breast J
The Breast Journal, Vol 2024 (2024)

Schlagwörter: Breast Neoplasms / drug therapy, Receptor, ErbB-2, receptor, receptors, Receptor, ErbB-2 / metabolism, chemotherapy, Class I Phosphatidylinositol 3-Kinases / genetics, ErbB-2, 0302 clinical medicine, breast neoplasms, estrogen, antineoplastic agents, RC254-282, Breast Neoplasms / mortality, breast tumor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Receptors, Estrogen / metabolism, Breast Neoplasms / therapy, Receptors, Progesterone / metabolism, Receptors, Estrogen, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal / therapeutic use, Breast Neoplasms / pathology, Female, PIK3CA mutations, Public aspects of medicine, RA1-1270, Receptors, Progesterone, Research Article, Adult, tumor, disease-free survival, Antineoplastic Agents, Hormonal, Class I Phosphatidylinositol 3-Kinases, Croatia, Neoplasm Recurrence, Local / genetics, Breast Neoplasms, progesterone, Disease-Free Survival, 03 medical and health sciences, adjuvant, local, Biomarkers, Tumor, Humans, Retrospective Studies, Aged, Receptor, ErbB-2 / genetics, biomarkers, neoplasm recurrence, hormonal, Biomarkers, Tumor / genetics, Breast Neoplasms / genetics, Mutation, mutation, Neoplasm Recurrence, Local

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39742376
https://doaj.org/article/58fd4feb40884d6bb8fd7ad6d6f40a50
https://onlinelibrary.wiley.com/doi/10.1155/2024/5648845
https://doi.org/10.1155/2024/5648845
https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.e12512
https://doi.org/10.1200/JCO.2024.42.16_suppl.e12512
https://urn.nsk.hr/urn:nbn:hr:105:788167
https://doi.org/10.1155/2024/5648845

Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management

Autoren: Lisa M. Gudenkauf Struan Gray Brian D. Gonzalez et al.

Quelle: Gudenkauf, L M, Gray, S, Gonzalez, B D, Sachdeva, A & Autio, K 2024, 'Balancing Hormone Therapy : Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management', American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting, vol. 44, no. 3, e433126. https://doi.org/10.1200/EDBK_433126

Schlagwörter: Male, Antineoplastic Agents, Hormonal/therapeutic use, Antineoplastic Agents, Hormonal, Quality of Life, Humans, Prostatic Neoplasms, Disease Management, Prostatic Neoplasms/drug therapy, Androgen Antagonists, Androgen Antagonists/therapeutic use, 3. Good health

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38788186
https://research.manchester.ac.uk/en/publications/645364cb-50cc-4926-bc87-665d981772cd
https://pure.manchester.ac.uk/ws/files/338155690/Gudenkauf_2024_-balancing-hormone-therapy-mitigating-adverse-effects-of-androgen-deprivation-therapy-and-exploring.pdf
https://doi.org/10.1200/EDBK_433126

Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients

Autoren: Woolpert, Kirsten M. Schmidt, Julie A. Ahern, Thomas P. et al.

Quelle: Breast Cancer Res
Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024)
Woolpert, K M, Schmidt, J A, Ahern, T P, Hjorth, C F, Farkas, D K, Ejlertsen, B, Collin, L J, Lash, T L & Cronin-Fenton, D P 2024, ' Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients ', Breast cancer research : BCR, vol. 26, no. 1, 59 . https://doi.org/10.1186/s13058-024-01819-4
Woolpert, K M, Schmidt, J A, Ahern, T P, Hjorth, C F, Farkas, D K, Ejlertsen, B, Collin, L J, Lash, T L & Cronin-Fenton, D P 2024, 'Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients', Breast Cancer Research, vol. 26, no. 1, 59, pp. 59. https://doi.org/10.1186/s13058-024-01819-4

Schlagwörter: Antineoplastic Agents, Hormonal/therapeutic use, Clinical characteristics, Antineoplastic Agents, Hormonal, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Breast Neoplasms, Comorbidities, Medication Adherence, 3. Good health, Premenopausal breast cancer, 03 medical and health sciences, Adjuvant endocrine therapy, 0302 clinical medicine, Breast Neoplasms/drug therapy, Adherence, Chemotherapy, Adjuvant, Humans, Female, Chronic medication use, RC254-282, Retrospective Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38589932
https://doaj.org/article/091fb63dec7f4ac986c7af6f5c78c063
https://curis.ku.dk/ws/files/389507441/s13058_024_01819_4.pdf
https://pure.au.dk/portal/en/publications/34fb27c9-f015-4a7f-ada6-027499740f99
https://doi.org/10.1186/s13058-024-01819-4
http://www.scopus.com/inward/record.url?scp=85190343814&partnerID=8YFLogxK

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

Autoren: M. Opdam V. van der Noort M. Kleijn et al.

Weitere Verfasser: M. Opdam V. van der Noort M. Kleijn et al.

Quelle: Breast Cancer Res Treat
Opdam, M, van der Noort, V, Kleijn, M, Glas, A, Mandjes, I, Kleiterp, S, Hilbers, F S, Kruger, D T, Bins, A D, de Jong, P C, Schiphorst, P P J B M, van Dalen, T, Flameling, B, Rietbroek, R C, Beeker, A, van den Heiligenberg, S M, Bakker, S D, Wymenga, A N M, Oving, I M, Bijlsma, R M, van Diest, P J, Vermorken, J B, van Tinteren, H & Linn, S C 2022, 'Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature', Breast Cancer Research and Treatment, vol. 194, no. 2, pp. 265-278. https://doi.org/10.1007/s10549-022-06618-z
Breast cancer research and treatment

Schlagwörter: Cancer Research, Antineoplastic Agents, Hormonal/therapeutic use, Antineoplastic Agents, Hormonal, Overtreatment, Endocrine treatment, MammaPrint 70-gene signature, Early breast cancer, Breast Neoplasms, Prognosis, Clinical Trial, 3. Good health, Postmenopause, Tamoxifen, 03 medical and health sciences, 0302 clinical medicine, Breast Neoplasms/drug therapy, Tamoxifen/therapeutic use, Oncology, Chemotherapy, Adjuvant, Randomized Controlled Trial, Journal Article, Humans, Postmenopausal, Female, Human medicine

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/35587322
https://research.vumc.nl/en/publications/0eb0b8eb-bf46-4093-94ac-d4d3435e55ac
https://dspace.library.uu.nl/handle/1874/446478
https://pure.amsterdamumc.nl/en/publications/3e600b58-c30b-4df6-8571-456fe87c7648
https://doi.org/10.1007/s10549-022-06618-z
https://hdl.handle.net/10067/1887780151162165141
https://repository.uantwerpen.be/docstore/d:irua:12883

5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast cancer: A population-based database study (2006–2016): a population-based database study (2006-2016)

Autoren: Yannick J.P.G. van den Biggelaar Josephina G. Kuiper Maurice J.C. van der Sangen et al.

Quelle: Breast Disease. 42:331-339

Schlagwörter: Breast Neoplasms/pathology, Antineoplastic Agents, Hormonal, Antineoplastic Agents, Breast Neoplasms, compliance, survival, survival analysis, 3. Good health, Tamoxifen, Breast cancer, Treatment Outcome, Tamoxifen/therapeutic use, SDG 3 - Good Health and Well-being, Chemotherapy, Adjuvant, adjuvant hormonal therapy, Chemotherapy, Humans, Female, Hormonal/therapeutic use, Adjuvant

Zugangs-URL: https://www.researchsquare.com/article/rs-1392722/latest.pdf
https://pubmed.ncbi.nlm.nih.gov/37927248
https://research.utwente.nl/en/publications/be06b1ef-ad1c-4c59-bb4a-d20bd9ebfee9

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials

Autoren: Rosie Bradley Jeremy Braybrooke Richard Gray et al.

Weitere Verfasser: Rosie Bradley Jeremy Braybrooke Richard Gray et al.

Quelle: Lancet Oncol
Bradley, R, Braybrooke, J, Gray, R, Hills, R K, Liu, Z, Pan, H, Peto, R, Dodwell, D, McGale, P, Taylor, C, Francis, P A, Gnant, M, Perrone, F, Regan, M M, Berry, R, Boddington, C, Clarke, M, Davies, C, Davies, L, Duane, F, Evans, V, Gay, J, Gettins, L, Godwin, J, James, S, Liu, H, MacKinnon, E, Mannu, G, McHugh, T, Morris, P, Read, S, Straiton, E, Jakesz, R, Fesl, C, Pagani, O, Gelber, R, De Laurentiis, M, De Placido, S, Gallo, C, Albain, K, Anderson, S, Arriagada, R, Bartlett, J, Bergsten-Nordström, E, Bliss, J, Brain, E, Carey, L, Coleman, R, Cuzick, J, Ejlertsen, B & Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2022, ' Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression : a patient-level meta-analysis of 7030 women from four randomised trials ', The Lancet Oncology, vol. 23, no. 3, pp. 382-392 . https://doi.org/10.1016/S1470-2045(21)00758-0
Bradley, R, Braybrooke, J, Gray, R, Hills, R K, Liu, Z, Pan, H, Peto, R, Dodwell, D, Mcgale, P, Taylor, C, Francis, P A, Gnant, M, Perrone, F, Regan, M M, Berry, R, Boddington, C, Clarke, M, Davies, C, Davies, L, Duane, F, Evans, V, Gay, J, Gettins, L, Godwin, J, James, S, Liu, H, Mackinnon, E, Mannu, G, Mchugh, T, Morris, P, Read, S, Straiton, E, Jakesz, R, Fesl, C, Pagani, O, Gelber, R, De Laurentiis, M, De Placido, S, Gallo, C, Albain, K, Anderson, S, Arriagada, R, Bartlett, J, Bergsten-nordström, E, Bliss, J, Brain, E, Carey, L, Coleman, R, Cuzick, J, Davidson, N, Del Mastro, L, Di Leo, A, Dignam, J, Dowsett, M, Ejlertsen, B, Goetz, M, Goodwin, P, Halpin-murphy, P, Hayes, D, Hill, C, Jagsi, R, Janni, W, Loibl, S, Mamounas, E P, Martín, M, Mukai, H, Nekljudova, V, Norton, L, Ohashi, Y, Pierce, L, Poortmans, P, Pritchard, K I, Raina, V, Rea, D, Robertson, J, Rutgers, E, Spanic, T, Sparano, J, Steger, G, Tang, G, Toi, M, Tutt, A, Viale, G, Wang, X, Whelan, T, Wilcken, N, Wolmark, N, Cameron, D, Bergh, J & Swain, S M 2022, ' Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials ', The Lancet Oncology, vol. 23, no. 3, pp. 382-392 . https://doi.org/10.1016/S1470-2045(21)00758-0

Schlagwörter: Breast Neoplasms/pathology, Antineoplastic Agents, Hormonal/therapeutic use, Antineoplastic Agents, Hormonal, Antineoplastic Agents, Breast Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Receptors, Chemotherapy, Humans, Adjuvant, Randomized Controlled Trials as Topic, Hormonal, Aromatase Inhibitors, Articles, Estrogen, 3. Good health, Tamoxifen, Neoplasm Recurrence, Local/drug therapy, Neoplasm Recurrence, Tamoxifen/therapeutic use, Local, Receptors, Estrogen, Chemotherapy, Adjuvant, Female, Aromatase Inhibitors/adverse effects, Neoplasm Recurrence, Local

Dateibeschreibung: application/pdf

Zugangs-URL: http://www.thelancet.com/article/S1470204521007580/pdf
https://pubmed.ncbi.nlm.nih.gov/35123662
http://hdl.handle.net/11588/890570
https://curis.ku.dk/ws/files/314836495/1_s2.0_S1470204521007580_main.pdf
https://www.pure.ed.ac.uk/ws/files/251776506/PIIS1470204521007580.pdf
https://hdl.handle.net/20.500.11820/cca1ad07-b6fb-4d9f-a5f5-d418002b61da
https://hdl.handle.net/11567/1156767
https://doi.org/10.1016/S1470-2045(21)00758-0
https://hdl.handle.net/11588/890570
https://doi.org/10.1016/S1470-2045(21)00758-0

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)

Autoren: Yeon Hee Park Jee Hyun Kim Hee Kyung Ahn et al.

Weitere Verfasser: Yeon Hee Park Jee Hyun Kim Hee Kyung Ahn et al.

Quelle: Cancer Res Treat

Schlagwörter: Breast Neoplasms / therapy, Androstadienes / pharmacology, Pyridines, Receptor, ErbB-2, Pyridines / therapeutic use, CDK4/6 inhibitor, Piperazines, Estrogen / analysis, Local / therapy, 0302 clinical medicine, Adjuvant / methods, Receptors, Antineoplastic Combined Chemotherapy Protocols, Multicenter Studies as Topic, Piperazines / pharmacology, Piperazines / therapeutic use, Protein Kinase Inhibitors / therapeutic use, Mastectomy, Estrogen / metabolism, Randomized Controlled Trials as Topic, 2. Zero hunger, Breast Neoplasms / mortality, Androstadienes / therapeutic use, Middle Aged, Progression-Free Survival, 3. Good health, Tamoxifen / therapeutic use, Receptors, Estrogen, Chemotherapy, Adjuvant, Pyridines / pharmacology, Breast Neoplasms / pathology, Original Article, Female, Receptor, Endocrine therapy, Adult, Antineoplastic Agents, Hormonal, Antineoplastic Agents, Breast Neoplasms, Progesterone / analysis, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Chemotherapy, Humans, Clinical Trials, Protein Kinase Inhibitors, Hormonal / therapeutic use, Hormonal / pharmacology, Phase II as Topic, Protein Kinase Inhibitors / pharmacology, Antineoplastic Combined Chemotherapy Protocols / pharmacology, Androstadienes, Neoplasm Recurrence, Local / pathology, Tamoxifen / pharmacology, ErbB-2 / analysis, Progesterone / metabolism, Breast neoplasms, Neoplasm Recurrence, Local, Local / mortality

Zugangs-URL: http://www.e-crt.org/upload/pdf/crt-2020-1246.pdf
https://pubmed.ncbi.nlm.nih.gov/33332933
http://www.e-crt.org/upload/pdf/crt-2020-1246.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291192
https://www.e-crt.org/journal/view.php?number=3193
https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/89435
https://snucm.elsevierpure.com/en/publications/implications-of-tamoxifen-resistance-in-palbociclib-efficacy-for-
https://pubmed.ncbi.nlm.nih.gov/33332933/

Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance

Autoren: Valentin H. Meissner Mira Woll Donna P. Ankerst et al.

Quelle: World J Urol

Schlagwörter: Male, Prostatectomy, 2. Zero hunger, ddc:610, Clinical Decision-Making [MeSH], Watchful Waiting [MeSH], Aged [MeSH], Risk Assessment [MeSH], Prostatic Neoplasms/mortality [MeSH], Kaplan-Meier Estimate [MeSH], Humans [MeSH], Active surveillance, Prostatic Neoplasms/pathology [MeSH], Middle Aged [MeSH], Radical prostatectomy, Original Article, Chemotherapy, Adjuvant [MeSH], Proportional Hazards Models [MeSH], Male [MeSH], Disease-Free Survival [MeSH], Prostatic Neoplasms/therapy [MeSH], Antineoplastic Agents, Hormonal/therapeutic use [MeSH], Favorable intermediate risk, Prostatectomy [MeSH], Radiotherapy, Adjuvant [MeSH], Oncological outcome, Prostate cancer, Antineoplastic Agents, Hormonal, Clinical Decision-Making, Prostatic Neoplasms, Kaplan-Meier Estimate, Middle Aged, Risk Assessment, Disease-Free Survival, ddc, 3. Good health, Chemotherapy, Adjuvant, Humans, Radiotherapy, Adjuvant, Watchful Waiting, Aged, Proportional Hazards Models

Dateibeschreibung: application/pdf

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00345-021-03717-2.pdf
https://pubmed.ncbi.nlm.nih.gov/33973043
https://link.springer.com/content/pdf/10.1007/s00345-021-03717-2.pdf
https://link.springer.com/article/10.1007/s00345-021-03717-2
https://www.ncbi.nlm.nih.gov/pubmed/33973043
https://europepmc.org/article/MED/33973043
https://pubmed.ncbi.nlm.nih.gov/33973043/
http://www.ncbi.nlm.nih.gov/pubmed/33973043
https://nbn-resolving.org/urn:nbn:de:bvb:384-opus4-920802
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/92080
https://doi.org/10.1007/s00345-021-03717-2
https://opus.bibliothek.uni-augsburg.de/opus4/files/92080/Meissner2021_Long-termAndPathologicalOutcom.pdf
https://repository.publisso.de/resource/frl:6447733
https://mediatum.ub.tum.de/doc/1638242/document.pdf

Fertility preserving management of early endometrial cancer in a patient cohort at the department of women’s health at the university of Tuebingen

Autoren: Jürgen Andress Jana Pasternak Christina Walter et al.

Quelle: Arch Gynecol Obstet

Schlagwörter: Adult, Antineoplastic Agents, Hormonal, Fertility Preservation, Gynecologic Oncology, Conservative Treatment, Endometrial Neoplasms, 3. Good health, 03 medical and health sciences, Fertility, Treatment Outcome, 0302 clinical medicine, Pregnancy, Germany, Endometrial Hyperplasia, Humans, Female, Endometrial Neoplasms/drug therapy [MeSH], Female [MeSH], Adult [MeSH], Endometrial Hyperplasia/pathology [MeSH], Humans [MeSH], Endometrial Hyperplasia/drug therapy [MeSH], Treatment Outcome [MeSH], Fertility [MeSH], Retrospective Studies [MeSH], Fertility Preservation/methods [MeSH], Organ Sparing Treatments/methods [MeSH], Fertility sparing treatment, Endometrial Neoplasms/pathology [MeSH], Complex atypical hyperplasia, Progestins/therapeutic use [MeSH], Antineoplastic Agents, Hormonal/administration, Germany [MeSH], Low-grade endometrial cancer, Progestins/administration, Antineoplastic Agents, Hormonal/therapeutic use [MeSH], Progestin agents, Conservative Treatment [MeSH], Pregnancy [MeSH], Progestins, Organ Sparing Treatments, Retrospective Studies

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00404-020-05905-8.pdf
https://pubmed.ncbi.nlm.nih.gov/33606091
https://pubmed.ncbi.nlm.nih.gov/33606091/
http://europepmc.org/article/MED/33606091
https://www.ncbi.nlm.nih.gov/pubmed/33606091
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164611
https://link.springer.com/content/pdf/10.1007/s00404-020-05905-8.pdf
https://link.springer.com/article/10.1007/s00404-020-05905-8
https://repository.publisso.de/resource/frl:6450650

Management and outcomes for older women with early breast cancer treated with primary endocrine therapy (PET)

Autoren: Thomas Hubbard Georgia Wright Jenna Morgan et al.

Weitere Verfasser: Thomas Hubbard Georgia Wright Jenna Morgan et al.

Quelle: Breast
Breast, Vol 77, Iss, Pp 103768-(2024)

Schlagwörter: Endocrine therapy, Antineoplastic Agents, Hormonal, Breast Neoplasms, Antineoplastic Agents, 03 medical and health sciences, 0302 clinical medicine, 80 and over, Humans, Prospective Studies, Older adult, Hormonal/therapeutic use, RC254-282, Aged, Aged, 80 and over, United Kingdom/epidemiology, Age Factors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, United Kingdom, 3. Good health, Tamoxifen, Treatment Outcome, Breast Neoplasms/mortality/drug therapy/therapy/pathology, Tamoxifen/therapeutic use, Multivariate Analysis, Original Article, Female, Breast neoplasms

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38996610
https://doaj.org/article/b788edaf2a2b4889850d66fb0a38d399

[18F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer

Autoren: Felix Dietlein Peter Mueller Carsten Kobe et al.

Quelle: Mol Imaging Biol
Molecular imaging and biology 23(2), 277-286 (2021). doi:10.1007/s11307-020-01546-0

Schlagwörter: Glutamate Carboxypeptidase II, Male, Fluorine Radioisotopes, Antineoplastic Agents, Hormonal, Prostatic Neoplasms, Prostate-Specific Antigen, 6. Clean water, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Androgen deprivation therapy, Glutamate Carboxypeptidase II/metabolism [MeSH], Aged [MeSH], Prostate-Specific Antigen/blood [MeSH], Prostatic Neoplasms/drug therapy [MeSH], Prostatic Neoplasms/pathology [MeSH], Neoplasm Recurrence, Local/pathology [MeSH], PET, Neoplasm Staging [MeSH], Male [MeSH], Neoplasm Recurrence, Local/diagnostic imaging [MeSH], Positron Emission Tomography Computed Tomography/methods [MeSH], Kallikreins/blood [MeSH], [, Research Article, Prostate cancer, Radiopharmaceuticals/pharmacokinetics [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Antigens, Surface/metabolism [MeSH], Prostatic Neoplasms/diagnostic imaging [MeSH], PSMA, Fluorine Radioisotopes [MeSH], Antineoplastic Agents, Hormonal/therapeutic use [MeSH], Neoplasm Recurrence, Local/drug therapy [MeSH], Positron Emission Tomography Computed Tomography, Antigens, Surface, Humans, Kallikreins, Neoplasm Recurrence, Local, Radiopharmaceuticals, Aged, Neoplasm Staging, Retrospective Studies

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s11307-020-01546-0.pdf
https://pubmed.ncbi.nlm.nih.gov/33006028
https://pubmed.ncbi.nlm.nih.gov/33006028/
https://europepmc.org/article/MED/33006028
https://link.springer.com/content/pdf/10.1007/s11307-020-01546-0.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910246/
https://link.springer.com/article/10.1007/s11307-020-01546-0
https://juser.fz-juelich.de/record/893306
https://repository.publisso.de/resource/frl:6468660

Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial

Autoren: David Krug René Baumann Katja Krockenberger et al.

Quelle: Strahlenther Onkol

Schlagwörter: Antineoplastic Agents, Hormonal, Esthetics, Radiotherapy, Adjuvant/methods [MeSH], Hot Flashes/chemically induced [MeSH], Radiotherapy, Conformal/methods [MeSH], Radiotherapy, Adjuvant/adverse effects [MeSH], Esthetics [MeSH], Breast Neoplasms/radiotherapy [MeSH], Original Article, Adverse events, Intensity modulated radiotherapy, Pain/etiology [MeSH], Radiation Dose Hypofractionation [MeSH], Radiotherapy, Conformal/adverse effects [MeSH], Breast Neoplasms/surgery [MeSH], Combined Modality Therapy [MeSH], Radiotherapy, Intensity-Modulated/methods [MeSH], Acute toxicity, Female [MeSH], Mastectomy, Segmental [MeSH], Humans [MeSH], Prospective Studies [MeSH], Breast Neoplasms/drug therapy [MeSH], Radiotherapy, Intensity-Modulated/adverse effects [MeSH], Chemotherapy, Adjuvant [MeSH], Antineoplastic Agents, Hormonal/adverse effects [MeSH], Radiation dermatitis, Pilot Projects [MeSH], Antineoplastic Agents, Hormonal/therapeutic use [MeSH], Treatment compliance, Radiodermatitis/etiology [MeSH], Pain, Breast Neoplasms, Pilot Projects, Mastectomy, Segmental, Combined Modality Therapy, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Chemotherapy, Adjuvant, Hot Flashes, Humans, Female, Radiation Dose Hypofractionation, Radiotherapy, Adjuvant, Prospective Studies, Radiotherapy, Intensity-Modulated, Radiodermatitis, Radiotherapy, Conformal

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00066-020-01689-7.pdf
https://pubmed.ncbi.nlm.nih.gov/33001241
https://jglobal.jst.go.jp/en/detail?JGLOBAL_ID=202102280079403715
https://link.springer.com/article/10.1007/s00066-020-01689-7
https://link.springer.com/content/pdf/10.1007/s00066-020-01689-7.pdf
https://pubmed.ncbi.nlm.nih.gov/33001241/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801347
https://europepmc.org/article/PMC/PMC7801347
https://repository.publisso.de/resource/frl:6443222

First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer

Autoren: Johannes Ettl Sophie-Isabelle Anders Alexander Hapfelmeier et al.

Quelle: Arch Gynecol Obstet

Schlagwörter: Adult, Endopredict, Aged [MeSH], Receptor, ErbB-2/metabolism [MeSH], Adjuvant chemotherapy, Breast cancer, Proportional Hazards Models [MeSH], Endocrine therapy, Breast Neoplasms/mortality [MeSH], Female [MeSH], Receptors, Estrogen/metabolism [MeSH], Adult [MeSH], Kaplan-Meier Estimate [MeSH], Humans [MeSH], Prognostic biomarker, Prospective Studies [MeSH], Treatment Outcome [MeSH], Breast Neoplasms/drug therapy [MeSH], Predictive Value of Tests [MeSH], Breast Neoplasms/metabolism [MeSH], Middle Aged [MeSH], Predictive biomarker, Family Characteristics [MeSH], Chemotherapy, Adjuvant [MeSH], Disease-Free Survival [MeSH], Prognosis [MeSH], Antineoplastic Agents, Hormonal/therapeutic use [MeSH], Neoplasm Recurrence, Local/drug therapy [MeSH], Gynecologic Oncology, Real-Time Polymerase Chain Reaction [MeSH], Antineoplastic Agents, Hormonal, Receptor, ErbB-2, Breast Neoplasms, Kaplan-Meier Estimate, Real-Time Polymerase Chain Reaction, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Humans, Prospective Studies, Aged, Proportional Hazards Models, 2. Zero hunger, Family Characteristics, Middle Aged, Prognosis, ddc, 3. Good health, Treatment Outcome, Receptors, Estrogen, Chemotherapy, Adjuvant, Female, Neoplasm Recurrence, Local

Dateibeschreibung: application/pdf

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00404-020-05771-4.pdf
https://pubmed.ncbi.nlm.nih.gov/32902674
https://www.ncbi.nlm.nih.gov/pubmed/32902674
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584549
https://pubmed.ncbi.nlm.nih.gov/32902674/
https://link.springer.com/article/10.1007/s00404-020-05771-4
https://link.springer.com/content/pdf/10.1007/s00404-020-05771-4.pdf
https://repository.publisso.de/resource/frl:6466680
https://mediatum.ub.tum.de/doc/1586263/document.pdf

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer

Autoren: Vincent Walter Chiara Fischer Thomas M. Deutsch et al.

Quelle: Breast Cancer Res Treat

Schlagwörter: Adult, Neoplasms, Hormone-Dependent/drug therapy [MeSH], Aged [MeSH], Receptors, Progesterone/analysis [MeSH], Receptor, ErbB-2/analysis [MeSH], Receptor, ErbB-2/antagonists, Biomarkers, Tumor [MeSH], Distant metastasis, Breast Neoplasms/pathology [MeSH], Progesterone receptor (PR), Estrogen receptor (ER), Adolescent [MeSH], Female [MeSH], Receptor status discordance, Follow-Up Studies [MeSH], Metastatic breast cancer, Neoplasms, Hormone-Dependent/pathology [MeSH], Adult [MeSH], Kaplan-Meier Estimate [MeSH], Humans [MeSH], Neoplasm Metastasis [MeSH], Clinical Trial, Breast Neoplasms/drug therapy [MeSH], Breast Neoplasms/chemistry [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Neoplasm Proteins/antagonists, Estrogens [MeSH], Protein Kinase Inhibitors/therapeutic use [MeSH], Molecular Targeted Therapy [MeSH], Neoplasm Proteins/analysis [MeSH], Human epidermal growth factor receptor 2 (HER2), Progesterone [MeSH], Neoplasms, Hormone-Dependent/chemistry [MeSH], Germany [MeSH], Young Adult [MeSH], Antineoplastic Agents, Hormonal/therapeutic use [MeSH], Receptors, Estrogen/analysis [MeSH], Neoplasms, Hormone-Dependent, Adolescent, Antineoplastic Agents, Hormonal, Receptor, ErbB-2, Breast Neoplasms, Estrogens, Kaplan-Meier Estimate, Middle Aged, Neoplasm Proteins, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Germany, Biomarkers, Tumor, Humans, Female, Molecular Targeted Therapy, Neoplasm Metastasis, Protein Kinase Inhibitors, Progesterone, Aged, Follow-Up Studies

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s10549-020-05746-8.pdf
https://pubmed.ncbi.nlm.nih.gov/32613540
https://www.ncbi.nlm.nih.gov/pubmed/32613540
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375990
https://www.link.springer.com/article/10.1007/s10549-020-05746-8?error=cookies_not_supported&code=dabbfc18-db5a-41c8-a3e4-4dc427f3ebde
https://pubmed.ncbi.nlm.nih.gov/32613540/
https://link.springer.com/article/10.1007/s10549-020-05746-8
https://link.springer.com/content/pdf/10.1007/s10549-020-05746-8.pdf
https://repository.publisso.de/resource/frl:6470716

Breast cancer: are long-term and intermittent endocrine therapies equally effective?

Autoren: Jutta Engel Gabriele Schubert-Fritschle Rebecca Emeny et al.

Quelle: J Cancer Res Clin Oncol

Schlagwörter: Review – Clinical Oncology, Antineoplastic Agents, Hormonal, Breast Neoplasms, Middle Aged, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Meta-Analysis as Topic, Chemotherapy, Adjuvant, Humans, Female, Neoplasm Metastasis, Breast Neoplasms/diagnostic imaging [MeSH], Female [MeSH], Aged [MeSH], Humans [MeSH], Metastasis, Neoplasm Metastasis [MeSH], Breast cancer, Over-treatment, Breast Neoplasms/drug therapy [MeSH], Middle Aged [MeSH], Randomized Controlled Trials as Topic [MeSH], Chemotherapy, Adjuvant [MeSH], Survival, Antineoplastic Agents, Hormonal/therapeutic use [MeSH], Meta-Analysis as Topic [MeSH], Breast Neoplasms/pathology [MeSH], Long-term endocrine adjuvant therapy, Aged, Randomized Controlled Trials as Topic

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00432-020-03264-0.pdf
https://pubmed.ncbi.nlm.nih.gov/32472445
https://link.springer.com/article/10.1007/s00432-020-03264-0
https://www.ncbi.nlm.nih.gov/pubmed/32472445
https://jglobal.jst.go.jp/detail?JGLOBAL_ID=202002256827947820
https://epub.ub.uni-muenchen.de/73200/
https://pubmed.ncbi.nlm.nih.gov/32472445/
https://link.springer.com/content/pdf/10.1007/s00432-020-03264-0.pdf
https://repository.publisso.de/resource/frl:6467708
https://epub.ub.uni-muenchen.de/73200/